A randomized clinical trial of apatinib on an intermittent versus continuous dosing schedule in combination with docetaxel for advanced gastric cancer in second-line setting - Trial in progress

Yifu He(Anhui Provincial Hospital), Bing Hu(University of Waterloo), Jingping Niu(University of Science and Technology of China), Xiaowen Hu(Lanzhou University), Ying Yan(East China University of Science and Technology), G. Wang(Anhui Provincial Hospital), Sun Yu(University of Science and Technology of China), Cheng Ji(Anhui Provincial Hospital), Wei Chen(Zhejiang Sci-Tech University), Ke Li(Xi'an University of Science and Technology), Tingjuan Xu(Anhui Provincial Hospital), Shusheng Wu(University of Science and Technology of China), L. Cao(University of Science and Technology of China), Huiqin Luo(University of Science and Technology of China), H. Li(University of Science and Technology of China), Huijun Xu(University of Science and Technology of China)
Annals of Oncology
June 1, 2018
10.1093/annonc/mdy151.094
Cited by 0

Related Papers

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
|JAMA|2021|821
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
Facile Autoreduction of Iron Oxide/Carbon Nanotube Encapsulates
|Journal of the American Chemical Society|2006|270
Nanosheet-constructed porous BiOCl with dominant {001} facets for superior photosensitized degradation
|Nanoscale|2012|249
Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
|癌症：英文版|2021|207